1. Cancer Discov. 2011 Jul;1(2):98-9. doi: 10.1158/2159-8290.CD-11-0118.

New insight puts CRAF in sight as a therapeutic target.

Rebocho AP(1), Marais R.

Author information:
(1)Signal Transduction Team, Division of Tumour Biology, The Institute of Cancer 
Research, London, United Kingdom.

Comment on
    Cancer Discov. 2011 Jul;1(2):128-36. doi: 10.1158/2159-8290.CD-10-0044.

By selectively depleting components of the RAF-MEK-ERK pathway in transgenic 
mice, it is now shown in 2 studies that CRAF is critical for signaling to MEK 
downstream of oncogenic Kras and that BRAF is not required.

DOI: 10.1158/2159-8290.CD-11-0118
PMCID: PMC3272431
PMID: 22318779 [Indexed for MEDLINE]